PTO/SB/14 (11-08)
`Approved for use through 06/30/2010. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respondto a collection of information unless it contains a valid OMB control number.
`
`Attorney Docket Number|38938-719.101
`Application Data Sheet 37 CFR 1.76
`
`—‘AppicaionNumber
`
`Title of Invention
`
`The application data sheet is part of the provisional or nonprovisional application for whichit is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`
`document may be printed and included in a paperfiled application.
`
`Secrecy Order 37 CFR 5.2
`[]
`Portionsorall of the application associated with this Application Data Sheet mayfall under a Secrecy Order pursuantto
`
`37 CFR 5.2 (Paperfilers only. Applications that fall under Secrecy Order may notbefiled electronically.)
`
`
`
`Applicant Information:
`
`Prefix
`
`US
`
`Applicant 1
`
`Applicant Authority @) Inventor|(Legal Representative under 35 U.S.C. 117 |Party of Interest under 35 U.S.C. 118 |
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Serge
`SAXONOV
`
`
`
`ResidenceInformation (Select One) @ US Residency
`© Non US Residency
`(©) Active US Military Service
`
`State/Province
`
`
`
`
`
` Country of Residencd’| US
`
`
`Citizenship under 37 CFR 1.41(b)
`
`
`Mailing Address of Applicant:
`Address1
`|
`10 De Anza Court
`
`METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS
`
`
` Total Number of Drawing Sheets(if any)
`
`
`
`
`Address 2
`
`
`
`
`
`
`
`
`
`
`
`All
`Inventors Must Be Listed - Additional
`Inventor Information blocks may be
`
`generated within this form by selecting the Add button.
`
`
`CorrespondenceInformation:
`Enter either Customer Numberor complete the CorrespondenceInformation section below.
`For further information see 37 CFR 1.33(a).
`
`[_] An Addressis being provided for the correspondence Information ofthis application.
`
`Customer Number Email Address
`
`
`
`_ dprouty@wsgr.com
`
`Application Information:
`
`
`Title of the Invention
`METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS
`
`Attorney Docket Number;
`
`38938-719.101
`
`Small Entity Status Claimed
`
`[_|
`
`
`
`Subject Matter
`
`Utility
`
`Suggested Technology Center (if any)
`
`EFS Web2.2.2
`
`Suggested Figure for Publication (if any)
`
`

`

`PTO/SB/14 (11-08)
`Approved for use through 06/30/2010. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|38938-719.101
`
`
`Application Number
`
`
` Application Data Sheet 37 CFR 1.76
`
`b
`
`
`
`METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS
`Title of Invention
`
`
`Publication Information:
`
`[|] Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. | hereby request that the attached application not be published under 35
`C] U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will notbe the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen monthsafterfiling.
`
`
`
`Representative Information:
`
`
`Representative information should be provided forall practitioners having a powerof attorney in the application. Providing
`
`this information in the Application Data Sheet does not constitute a powerof attorney in the application (see 37 CFR 1.32).
`
`Enter either Customer Number or complete the Representative Name section below.If both sections
`
`are completed the Customer Number will be used for the Representative Information during processing.
`
`
`
`
`Please Select One:
`
`Customer Number
`
`
`@ Customer Number
`021971
`
`
`
`
`
`© US PatentPractitioner
`
`©) Limited Recognition (37 CFR 11.9)
`
`
`
`
`
`
`
`
`
`Domestic Benefit/National Stage Information:
`
`This section allows for the applicantto either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by
`35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be madepart of the© Specification
`
`Application Number
`
`Continuity Type
`
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`
`Foreign Priority Information:
`This section allows for the applicantto claim benefit of foreign priority and to identify any prior foreign application for which priority is
`not claimed. Providing this information in the application data sheetconstitutes the claim for priority as required by 35 U.S.C. 119(b)
`and 37 CFR 1.55(a).
`
`Application Number
`
`
`ParentFiling Date (YYYY-MM-DD)
`Priority Claimed
`
`
`© Yes @ No
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`
`Add button.
`If the Assignee is an Organization check here.
`
`AssigneeInformation:
`Providing this information in the application data sheet does not substitute for compliance with any requirementof part 3 of Title 37
`of the CFR to have an assignment recordedin the Office.
`
`Assignee 1
`
`EFS Web 2.2.2
`
`

`

`PTO/SB/14 (11-08)
`Approved for use through 06/30/2010. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contro] number.
`
`Attorney Docket Number|38938-719.101
`
`Application Data Sheet 37 CFR 1.76 Application Number
`
`Title of Invention
`
`METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS
`
`QuantaLife Incorporated
`Organization Name
`Mailing Address Information:
`
`Address1
`
`Address 2
`
`7068 Koll Center Pkwy, Suite 401
`
`Email Address
`
`
`
`
`
`
`
`
`
`Additional Assignee Data may be generated within this form by selecting the Add
`
`button.
`
`
`
`|
`
`
`
`Signature:
`
`A signature of the applicant oyfepresentative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37
`¥
`
`
`
`
`Seidel, Ph.D., Patent Agent
`
`Registration Number
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Timewill vary depending uponthe individual case. Any comments on the amountoftime you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMSTO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.2
`
`

`

`Privacy Act Statement
`
`
`
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for thecollection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for whichthe informationis
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonmentofthe application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information-on this form will be treated confidentiallyto the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the
`Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Departmentof Justice to determine whetherthe
`Freedom ofInformation Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidenceto a court, magistrate, or
`administrative tribunal, including disclosures to opposing counselin the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Memberof Congress submitting a request involving an individual,
`to whom the record pertains, whenthe individual has requested assistance from the Memberwith respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having needfor the inforrnation in order
`to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended,
`pursuant to § U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a
`routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35
`U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during
`an inspection of records conducted by GSAaspart of that agency's responsibility to recommend improvements in records management
`practices and programs, underauthority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA
`regulations governing inspection of recordsfor this purpose, and any other relevant (i.e., GSA or Commerce)directive. Such disclosure
`shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuantto
`35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR
`1.14, as a routine use, to the public if the record wasfiled in an application which became abandonedorin which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency,if the USPTO
`becomesawareof a violation or potential violation of law or regulation.
`
`
`
`EFS Web 2.2.2
`
`
`
`